Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 2
1966 3
1967 2
1975 2
1996 3
1999 1
2000 1
2002 2
2004 1
2006 1
2007 8
2008 7
2009 8
2010 9
2011 17
2012 23
2013 24
2014 23
2015 14
2016 28
2017 14
2018 6
2019 12
2020 14
2021 20
2022 26
2023 23
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

258 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Thrassou
Page 1
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Marso SP, et al. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. N Engl J Med. 2016. PMID: 27295427 Free PMC article. Clinical Trial.
W'ALK' Into the Next Stage.
Toyokawa G, Seto T, Takenoyama M, Ichinose Y. Toyokawa G, et al. Clin Lung Cancer. 2017 Mar;18(2):122-126. doi: 10.1016/j.cllc.2016.10.005. Epub 2016 Oct 26. Clin Lung Cancer. 2017. PMID: 27865624 Review.
Furthermore, various resistance mechanisms against ALKis have been gradually elucidated, and treatment strategies according to such resistance have been proposed. In addition, novel ALKis exhibit good antitumor efficacy for brain metastases. Thus, we now know much a …
Furthermore, various resistance mechanisms against ALKis have been gradually elucidated, and treatment strategies according to such r …
A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer.
Zheng B, Jiang H, Yang W, Li Y, Liang B, Zhu J, Chen N, Chen M, Zhang M. Zheng B, et al. Cancer Med. 2023 Aug;12(15):15983-15997. doi: 10.1002/cam4.6241. Epub 2023 Jun 19. Cancer Med. 2023. PMID: 37334877 Free PMC article.
OBJECTIVE: To date, no direct comparisons have compared the effectiveness of all ALK inhibitors (ALKis) against ALK-positive non-small cell lung cancer (NSCLC). The aim of the present study was to investigate the efficacy and safety of ALKis in ALK-positive NSCLC. . …
OBJECTIVE: To date, no direct comparisons have compared the effectiveness of all ALK inhibitors (ALKis) against ALK-positive non-smal …
Incidence of severe critical events in paediatric anaesthesia (APRICOT): a prospective multicentre observational study in 261 hospitals in Europe.
Habre W, Disma N, Virag K, Becke K, Hansen TG, Jöhr M, Leva B, Morton NS, Vermeulen PM, Zielinska M, Boda K, Veyckemans F; APRICOT Group of the European Society of Anaesthesiology Clinical Trial Network. Habre W, et al. Lancet Respir Med. 2017 May;5(5):412-425. doi: 10.1016/S2213-2600(17)30116-9. Epub 2017 Mar 28. Lancet Respir Med. 2017. PMID: 28363725
Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data.
Birtas Atesoglu E, Gulbas Z, Uzay A, Ozcan M, Ozkalemkas F, Dal MS, Kalyon H, Akay OM, Deveci B, Bekoz H, Sevindik OG, Toptas T, Yilmaz F, Koyun D, Alkis N, Alacacioglu I, Sonmez M, Yavasoglu I, Tombak A, Mehtap O, Kurnaz F, Yuce OK, Karakus V, Turgut M, Kurekci DD, Ayer M, Keklik M, Buyuktas D, Ozbalak M, Ferhanoglu B. Birtas Atesoglu E, et al. Hematol Oncol. 2023 Oct;41(4):663-673. doi: 10.1002/hon.3174. Epub 2023 May 22. Hematol Oncol. 2023. PMID: 37211991
The overall survival benefit in Chinese ALK+ NSCLC patients received targeted therapies.
Tian G, Zhao X, Nie J, Dai L, Hu W, Zhang J, Chen X, Han J, Ma X, Wu D, Han S, Long J, Wang Y, Zhang Z, Fang J. Tian G, et al. J Thorac Dis. 2022 Jun;14(6):2201-2212. doi: 10.21037/jtd-22-622. J Thorac Dis. 2022. PMID: 35813748 Free PMC article.
Patients treated with 2 types of ALKi had better survival than those treated with 1 ALKi (mOS: 45.8 vs. 21.3 months, P=0.003), but no such survival benefit was observed in patients treated with 3 ALKis (P=0.366). CONCLUSIONS: ALKis have been shown to be clinically e …
Patients treated with 2 types of ALKi had better survival than those treated with 1 ALKi (mOS: 45.8 vs. 21.3 months, P=0.003), but no such s …
Anaplastic Lymphoma Kinase Inhibitors for Therapy of Neuroblastoma in Adults.
Stiefel J, Kushner BH, Roberts SS, Iglesias-Cardenas F, Kramer K, Modak S. Stiefel J, et al. JCO Precis Oncol. 2023 Aug;7:e2300138. doi: 10.1200/PO.23.00138. JCO Precis Oncol. 2023. PMID: 37561984
AON is enriched for somatic mutations including anaplastic lymphoma kinase (ALK), deemed to be an oncogenic driver in NB. ALK inhibitors (ALKis), therefore, have the potential to be of therapeutic benefit. ...Median survival from start of first ALKi was 43 26 months. CONCL …
AON is enriched for somatic mutations including anaplastic lymphoma kinase (ALK), deemed to be an oncogenic driver in NB. ALK inhibitors ( …
First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-Analysis.
Wu KL, Chen HL, Tsai YM, Lee TH, Chang HM, Tsai YC, Chuang CH, Chang YC, Tu YK, Yang CJ, Hung JY, Chong IW. Wu KL, et al. J Clin Med. 2021 Sep 25;10(19):4376. doi: 10.3390/jcm10194376. J Clin Med. 2021. PMID: 34640394 Free PMC article. Review.
To date, no head-to-head comparison of these newer generation ALKIs has been made, and different efficacies of ALKIs may present across ethnicity. This study aims to compare newer generation ALKIs for treatment efficacy in Asian groups using network meta-anal …
To date, no head-to-head comparison of these newer generation ALKIs has been made, and different efficacies of ALKIs may prese …
Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer.
Chuang CH, Chen HL, Chang HM, Tsai YC, Wu KL, Chen IH, Chen KC, Lee JY, Chang YC, Chen CL, Tu YK, Hung JY, Yang CJ, Chong IW. Chuang CH, et al. Cancers (Basel). 2021 Apr 19;13(8):1966. doi: 10.3390/cancers13081966. Cancers (Basel). 2021. PMID: 33921762 Free PMC article. Review.
We conducted this systematic review and network meta-analysis to provide a ranking of ALKIs for treatment-naive ALK-positive patients in terms of PFS, ORR, and AEs. ...Low-dose alectinib had the lowest AE risk among the available ALKIs. Further head-to-head large-sc …
We conducted this systematic review and network meta-analysis to provide a ranking of ALKIs for treatment-naive ALK-positive patients …
258 results